NAC for Mental Health: OCD, Addiction, and Depression

← Back to articles

N-acetylcysteine (NAC) is best known as the hospital antidote for acetaminophen overdose. Over the past two decades, a growing body of psychiatric research has tested NAC as an add-on therapy for OCD, addiction, and depression — with results that have made it one of the more serious nutraceutical candidates in psychiatry.

The Glutamate-Glutathione Connection

NAC works through two relevant pathways. As a cysteine donor, it replenishes glutathione, the brain's main antioxidant. More importantly for psychiatric effects, NAC modulates the cystine-glutamate antiporter, which regulates extracellular glutamate. Disrupted glutamate signaling is implicated in addiction, OCD, and treatment-resistant depression.

NAC for OCD

A 2012 double-blind RCT (Afshar et al., Journal of Clinical Psychiatry) tested NAC at 2,400 mg/day as an SSRI add-on in patients with treatment-refractory OCD. At 12 weeks, the NAC group showed significantly larger reductions in Y-BOCS scores (the standard OCD severity scale) than placebo. A 2024 meta-analysis (Hinkle et al., Frontiers in Psychiatry) pooled six randomized trials of NAC augmentation in adult OCD (n=195). It concluded NAC at 2,000–3,000 mg/day may benefit moderate-to-severe OCD and is generally well tolerated, but called for larger trials to confirm. Of five clear adjunctive trials, four showed significant Y-BOCS reductions; one 20-week study did not. The evidence is best characterized as promising but not definitive.

NAC for Addiction

Multiple RCTs have found NAC reducing craving and use in cannabis and cocaine dependence. A 2012 RCT by Gray et al. in cannabis-using adolescents (1,200 mg twice daily for 8 weeks) doubled the odds of cannabis-negative urine drug screens compared to placebo. Larger follow-up trials in adults have been more mixed, with effects most evident in specific subgroups. Mechanism: chronic drug use disrupts the cystine-glutamate exchanger, and NAC appears to restore it.

Depression and Dosing

Several RCTs have found NAC producing antidepressant effects, particularly in bipolar depression and in cases with elevated inflammatory markers. A 2008 trial by Berk and colleagues showed NAC 1,000 mg twice daily reduced depressive symptoms in bipolar disorder over 24 weeks. Evidence is not strong enough for first-line use but supports adjunct trials in treatment-resistant cases. Most psychiatric NAC research uses 1,800–3,000 mg/day in divided doses. The most common side effect is gastrointestinal upset; nausea, heartburn, and diarrhea typically resolve with food. Anyone taking NAC alongside psychiatric medications, blood thinners, or nitroglycerin should clear it with their prescribing physician.